ATS 2019 Virtual Final Program

515 The Derivation/Validation of the Severe Asthma Questionnaire (SAQ)-a New Measure of Quality of Life in Severe Asthma/ R. Jones, M. Hyland, J. Lanario, M. Masoli, Plymouth, United Kingdom, p.A4074 516 The Association Between Asthma Control and Psychological Well-Being in London Secondary School Students with Asthma/ K. Harris, G. Mosler, J.M. Grigg, London, United Kingdom, p.A4075 517 Age Dependent Differences in Seasonal Versus Perennial Allergen Sensitivity in Association with Severe Asthma/ R. Wojcik, M.L. Fajt, J.V. Fahy, E.R. Bleecker, D.A. Meyers, N.N. Jarjour, M. Castro, E. Israel, B.D. Levy, W. Phipatanakul, A.M. Fitzpatrick, S.C. Erzurum, B.M. Gaston, S.E. Wenzel, W.C. Moore, A.T. Hastie, Pittsburgh, PA, p.A4076 518 The Impact of Severe Asthma on Patient Autonomy: A Qualitative Study/ D. Eassey, H.K. Reddel, K. Ryan, L. Smith, Sydney, Australia, p.A4077 519 Indirect Costs Due to Lost Work Time for Patients with Asthma Who Received Global Initiative for Asthma (GINA) Step 4/5 Therapy: Analysis of United States Administrative Claims Data/ R.A. Settipane, J.L. Kreindler, Y. Chung, J. Tkacz, Providence, RI, p.A4078 CLINICAL RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION B103 ILD: THERAPY 2:15 p.m. - 4:15 p.m. KBHCCD Room C140/C142 (Level 1) Abstract Summaries 2:15-2:45 Viewing/Discussion 2:45-4:15 Chairing: J. Oldham, MD, MS, Sacramento, CA J. Solomon, BS, MD, Denver, CO J. Behr, MD, Munich, Germany 101 Survival Benefit of Corticosteroid and Intravenous Cyclophosphamide Therapy in Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Propensity Score-Matched Analysis/ H. Hozumi, H. Hasegawa, K. Miyashita, H. Yasui, Y. Suzuki, M. Kono, M. Karayama, K. Furuhashi, D. Hashimoto, N. Enomoto, T. Fujisawa, N. Inui, Y. Nakamura, K. Yokomura, H. Nakamura, T. Suda, Hamamatsu, Japan, p.A4079 102 Circulating Krebs von den Lungen and CC Chemokine Lligand 2 Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Immunosuppressive Therapy/ D.P. Tashkin, E.R. Volkmann, N. Li, M.D. Roth, G.H. Kim, J. Goldin, R.M. Elashoff, S. Assassi, Los Angeles, CA, p.A4080 103 A Pilot Randomised Controlled Trial of Ambulatory Oxygen Versus Air Via Portable Concentrator in Fibrotic Interstitial Lung Disease/ Y.H. Khor, N. Goh, B. Miller, I. Glaspole, A.E. Holland, C.F. McDonald, Melbourne, Australia, p.A4081 104 Nintedanib Plus Sildenafil in Patients with IPF and Severely Impaired Gas Exchange: Subgroup Analysis by Presence of Emphysema/ V. Cottin, M. Kolb, A. Prasse, B. Bondue, B. Schinzel, S. Stowasser, M. Quaresma, A. Wells, Lyon, France, p.A4082 105 Outcome of Third Line Therapies in Sarcoidosis/ R.P. Baughman, M. Sturdivant, L. Grate, E.E. Lower, Cincinnati, OH, p.A4083 106 US National Pulmonary Alveolar Proteinosis Registry: Update on Differential Diagnosis, Clinical Manifestations, and Current Therapy/ B.C. Carey, C. McCarthy, M. Klingler, H. Greenberg, C. Chalk, A. Toth, M. Brelsford, T.S. Wang, J. Krischer, B.C. Trapnell, Cincinnati, OH, p.A4084 107 Effect of Nintedanib on Biomarkers of Extracellular Matrix (ECM) Turnover and FVC Decline in Patients with IPF: Results from the INMARK Study/ T.M. Maher, S. Stowasser, Y. Nishioka, E.S. White, V. Cottin, I. Noth, M. Selman, K.B. Rohr, D. Wachtlin, C. Ittrich, C. Diefenbach, R.G. Jenkins, London, United Kingdom, p.A4085 108 Efficacy and Safety of Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease (SSc-ILD): Results from the Phase IIb RISE-SSc Study/ O. Distler, Y. Allanore, C. Denton, M. Kuwana, M. Matucci-Cerinic, J.E. Pope, J. de Oliveira Pena, K. Laapas, Z. Yao, F. Behmenburg, M. Hemmrich, D. Khanna, Zurich, Switzerland, p.A4086 109 Targeting Myofibroblasts for Novel Imaging and Therapeutic Applications in Idiopathic Pulmonary Fibrosis/ S.U. Hettiarachchi, Y.H. Li, F.H. Zhang, E. Puchulu-Campanella, J. Roy, S. Lindeman, K. Tsoyi, M. Srinivasarao, B. Athenson, C. Nickerson-Nutter, I.O. Rosas, P.S. Low, West Lafayette, IN, p.A4087 110 Health-Related Quality of Life in Patients with IPF Treated with Nintedanib: Stratified Analysis from the INPULSIS ® Trials/ M. Kreuter, W. Wuyts, M. Wijsenbeek, S. Bajwah, S. Stowasser, N. Male, W. Stansen, N. Schoof, J. Swigris, Heidelberg, Germany, p.A4088 111 Differences in the Approach to Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE IPF) Between Expert Centres and General Pulmonologists: Results from an International Survey/ M. Kreuter, M. Polke, S.L.F. Walsh, H.R. Collard, N. Chaudhuri, S. Avdeev, J. Behr, T.J. Corte, K.R. Flaherty, M. Funke-Chambour, G. Calligaro, M.R.J. Kolb, Y. Kondoh, T.M. Maher, M. Molina-Molina, A. Morais, K. Moor, J. Morisset, C.A.D.C. Pereira, S.A. Quadrelli, M. Selman, A.E. Tzouvelekis, C. Vancheri, C. Valenzuela, V. Vicens Zygmunt, J. Wälscher, W. Wuyts, M. Wijsenbeek, V. Cottin, E. Bendstrup, Heidelberg, Germany, p.A4089 112 Metformin and Nintedanib Reduce Pulmonary Fibrosis in TGF-B Stimulated Fibroblasts/ A. Vu, T. Kottom, K. Schaefbauer, A.H. Limper, Rochester, MN, p.A4090 113 Sharing Experiences and Offering Mutual Support: An Evaluation of the Peer Connect Service for People with Pulmonary Fibrosis/ A.E. Holland, J. Lee, J. Maloney, J. Walsh, Melbourne, Australia, p.A4091 ATS 2019 • Dallas, TX MONDAY • MAY 20 209 MONDAY AFTERNOON